Results 61 to 70 of about 1,147,332 (293)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

Acta Pharmaceutica Sinica B, 2020
Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment.
Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu   +14 more
doaj   +1 more source

Angiogenesis in the pathogenesis of inflammatory joint and lung diseases [PDF]

, 2001
This paper reviews hypotheses about roles of angiogenesis in the pathogenesis of inflammatory disease in two organs, the synovial joint and the lung. Neovascularisation is a fundamental process for growth and tissue repair after injury.
Walsh, D.A., Pearson, C.I.
core  

Comparison of primary outcomes for bevacizumab versus other angiogenesis inhibitors.

, 2016
Comparison of primary outcomes for bevacizumab versus other angiogenesis inhibitors.
Meng Zhao (54299), Dan Xing (128154), Jie Wang (16762), Yang Yang (45629), Yawei Wang (1445449)   +4 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

MYCN oncogene and angiogenesis: Down-regulation of endothelial growth inhibitors in human neuroblastoma cells - Purification, structural, and functional characterization

, 2000
Angiogenesis, the formation of new blood vessels, is seen during embryonic development and tumor progression, but the mechanisms have remained unclear.
Murphy, C., Ahorn, H, Ahorn, H., Hatzi, E., Schweigerer, L, Ashman, K, Fotsis, T, Fotsis, T., Breit, S., Hatzi, E, Murphy, C, Tontsch, U, Breit, S, Ashman, K., Zoephel, A, Tontsch, U., Zoephel, A., Schweigerer, L.   +17 more
core   +5 more sources

Normal Wound Healing and Tumor Angiogenesis as a Game of Competitive Inhibition.

PLoS ONE, 2016
Both normal wound healing and tumor angiogenesis are mitigated by the sequential, carefully orchestrated release of growth stimulators and inhibitors.
Irina Kareva, Abdo Abou-Slaybi, Oliver Dodd, Olga Dashevsky, Giannoula Lakka Klement   +4 more
doaj   +1 more source

Development of a one-step embryonic stem cell-based assay for the screening of sprouting angiogenesis

BMC Biotechnology, 2007
Background Angiogenesis assays are important tools for the identification of regulatory molecules and the potential development of therapeutic strategies to modulate neovascularization.
Desroches-Castan Agnès, Hermant Bastien, Dubessay Marie-Laure, Prandini Marie-Hélène, Huber Philippe, Vittet Daniel   +5 more
doaj   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

The Hemostatic System and Angiogenesis in Malignancy

Neoplasia: An International Journal for Oncology Research, 2001
Coagulopathy and angiogenesis are among the most consistent host responses associated with cancer. These two respective processes, hitherto viewed as distinct, may in fact be functionally inseparable as blood coagulation and fibrinolysis, in their own ...
Marek Z. Wojtukiewicz, Ewa Sierko, Petr Klementt, Janusz Rak   +3 more
doaj   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source